title: Endogenous vasopressin contributes to hypothalamic-pituitary-adrenocortical alterations in aged rats.
abstract: The ageing process in animals and humans is thought to be accompanied by a gradual impairment of corticosteroid receptor function, which is reflected by increased pituitary-adrenocortical hormone secretion at baseline and a number of aberrant neuroendocrine function test results. The latter include the ACTH and corticosteroid responses to a combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) challenge. The excessive hormonal response to this test among aged individuals has been taken as indirect evidence of enhanced endogenous arginine vasopressin (AVP) release, which - together with peripherally administered CRH - is capable of overriding DEX-induced ACTH suppression. The current study was designed to explore the role of endogenous AVP in mediating excessive hypothalamic-pituitary-adrenocortical (HPA) activity in ageing. The combined DEX/CRH test was administered to aged (22-24 months old) Wistar rats and the effect of the AVP type 1 (V1) receptor antagonist, d(CH(2))(5)Tyr(Me)AVP, on ACTH release was studied. Infusion of the V1 receptor antagonist after DEX pretreatment and before CRH administration prevented the CRH-induced rise in ACTH secretion in comparison with vehicle-treated aged rats (area under the concentration-time curve: 699+/-479 versus 2896+/-759; P<0.01). This difference was absent in young (3 months old) control rats. In situ hybridization showed an increased number of AVP mRNA-expressing neurons in the parvocellular but not the magnocellular, portion of the hypothalamic paraventricular nucleus in DEX-pretreated aged rats. The number and synthetic activity of parvocellular neurons expressing CRH mRNA was also increased. We have concluded that the increased HPA activity in aged rats involves enhanced synthesis and release of AVP from parvocellular neurons, possibly secondary to impaired corticosteroid receptor function.
authors.affiliation: Max Planck Institute of Psychiatry, 80804 Munich, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hatzinger
authors.forename: C T
authors.initials: CT
authors.lastname: Wotjak
authors.forename: T
authors.initials: T
authors.lastname: Naruo
authors.forename: R
authors.initials: R
authors.lastname: Simchen
authors.forename: M E
authors.initials: ME
authors.lastname: Keck
authors.forename: R
authors.initials: R
authors.lastname: Landgraf
authors.forename: F
authors.initials: F
authors.lastname: Holsboer
authors.forename: I D
authors.initials: ID
authors.lastname: Neumann
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000375:Aging / Q000502:physiology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003345:Corticosterone / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology*; D008297:Male; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D014667:Vasopressins / Q000502:physiology*
chemical_list: D012333:RNA, Messenger; D014667:Vasopressins; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone